Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2021.677027 http://scihub22266oqcxt.onion/10.3389/fimmu.2021.677027 34168649!8218244!34168649     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34168649&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2021 ; 12 (ä): 677027 Nephropedia Template TP {{tp|p=34168649|t=2021. The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development |pdf=|usr=}}{{34168649}} gab.com Text The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=34168649 #FOAvip Epstein-Barr virus (EBV) is a human herpesvirus that is common among the global population, causing an enormous disease burden. EBV can directly cause infectious mononucleosis and is also associated with various malignancies and autoimmune diseases. In order to prevent primary infection and subsequent chronic disease, efforts have been made to develop a prophylactic vaccine against EBV in recent years, but there is still no vaccine in clinical use. The outbreak of the COVID-19 pandemic and the global cooperation in vaccine development against SARS-CoV-2 provide insights for next-generation antiviral vaccine design and opportunities for developing an effective prophylactic EBV vaccine. With improvements in antigen selection, vaccine platforms, formulation and evaluation systems, novel vaccines against EBV are expected to elicit dual protection against infection of both B lymphocytes and epithelial cells. This would provide sustainable immunity against EBV-associated malignancies, finally enabling the control of worldwide EBV infection and management of EBV-associated diseases. Twit Text FOAVip The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=34168649 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34168649 #FOAvip English Wikipedia <ref>{{Cite pmid|34168649}}</ref> The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development #MMPMID34168649 Sun C; Chen XC; Kang YF; Zeng MS Front Immunol 2021[]; 12 (ä): 677027 PMID34168649show ga Epstein-Barr virus (EBV) is a human herpesvirus that is common among the global population, causing an enormous disease burden. EBV can directly cause infectious mononucleosis and is also associated with various malignancies and autoimmune diseases. In order to prevent primary infection and subsequent chronic disease, efforts have been made to develop a prophylactic vaccine against EBV in recent years, but there is still no vaccine in clinical use. The outbreak of the COVID-19 pandemic and the global cooperation in vaccine development against SARS-CoV-2 provide insights for next-generation antiviral vaccine design and opportunities for developing an effective prophylactic EBV vaccine. With improvements in antigen selection, vaccine platforms, formulation and evaluation systems, novel vaccines against EBV are expected to elicit dual protection against infection of both B lymphocytes and epithelial cells. This would provide sustainable immunity against EBV-associated malignancies, finally enabling the control of worldwide EBV infection and management of EBV-associated diseases. |Animals[MESH] |COVID-19 Vaccines/*immunology[MESH] |COVID-19/*immunology[MESH] |Epstein-Barr Virus Infections/*immunology/prevention & control[MESH] |Herpesvirus 4, Human/*physiology[MESH] |Humans[MESH] |Lymphoproliferative Disorders/*immunology/prevention & control[MESH] |Pre-Exposure Prophylaxis[MESH] |SARS-CoV-2/*physiology[MESH]The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine De(epmc).pdf DeepDyve Pubget Overpricing